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Abstract
Background: Preterm infants requiring assisted ventilation are at significant risk of both pulmonary and cerebral injury. 
Inhaled Nitric Oxide, an effective therapy for pulmonary hypertension and hypoxic respiratory failure in the full term 
infant, has also been studied in preterm infants. The most recent Cochrane review of preterm infants includes 11 
studies and 3,370 participants. The results show a statistically significant reduction in the combined outcome of death 
or chronic lung disease (CLD) in two studies with routine use of iNO in intubated preterm infants. However, uncertainty 
remains as a larger study (Kinsella 2006) showed no significant benefit for iNO for this combined outcome. Also, trials 
that included very ill infants do not demonstrate significant benefit. One trial of iNO treatment at a later postnatal age 
reported a decrease in the incidence of CLD. The aim of this individual patient meta-analysis is to confirm or refute 
these potentially conflicting results and to determine the extent to which patient or treatment characteristics may 
explain the results and/or may predict benefit from inhaled Nitric Oxide in preterm infants.
Methods/Design: The Meta-Analysis of Preterm Patients on inhaled Nitric Oxide (MAPPiNO) Collaboration will 
perform an individual patient data meta-analysis to answer these important clinical questions. Studies will be included 
if preterm infants receiving assisted ventilation are randomized to receive inhaled Nitric Oxide or to a control group. 
The individual patient data provided by the Collaborators will be analyzed on an intention-to-treat basis where 
possible. Binary outcomes will be analyzed using log-binomial regression models and continuous outcomes will be 
analyzed using linear fixed effects models. Adjustments for trial differences will be made by including the trial variable 
in the model specification.
Discussion: Thirteen (13) trials, with a total of 3567 infants are eligible for inclusion in the MAPPiNO systematic review. 
To date 11 trials (n = 3298, 92% of available patients) have agreed to participate. Funding was successfully granted from 
Ikaria Inc as an unrestricted grant. A collaborative group was formed in 2006 with data collection commencing in 2007. 
It is anticipated that data analysis will commence in late 2009 with results being publicly available in 2010.
Background
Approximately 8-13% of infants are born prematurely
across developed countries. Preterm delivery accounts for
75-80% of all neonatal morbidity and mortality [1,2].
Although survival rates have markedly improved in recent
decades, premature infants requiring assisted ventilation are
still at significant risk of both pulmonary and cerebral
injury.
An estimated 75% of the infants with a birth weight less
than 1000 grams develop respiratory distress syndrome
(RDS), and nearly 30% are still oxygen dependent at a post-
menstrual age of 36 weeks [3]. The commonest definition
of chronic lung disease (CLD) is oxygen dependency or
respiratory support at 36 weeks postmenstrual age. Infants
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with severe CLD remain at high risk for pulmonary morbid-
ity and mortality during the first two years of life [4]. In
addition, long-term neurodevelopmental impairments asso-
ciated with cerebral palsy, mental retardation, sensorineural
hearing loss, and visual impairment are frequently observed
in infants with CLD [5,6]. The incidence rate of these neu-
rodevelopmental impairments increases with decreasing
birth weight. Neonates with birth weights of 1501 to 2500
grams have an 8% incidence, compared with a 25% rate in
infants born weighing less than 1000 g [7].
Nitric Oxide (NO) relaxes vascular smooth muscle by
activating guanyl cyclase and leading to the production of
cyclic GMP [8]. The first experimental study in immature
lambs reported that exogenous inhaled NO (iNO) selec-
tively increased pulmonary blood flow and reduced pulmo-
nary artery pressure [9]. Studies in adults also show that
iNO improves ventilation/perfusion mismatch by selective
pulmonary vasodilation [10,11]. A meta-analysis showed
iNO improved oxygenation in approximately 50% of full
term or near term infants with pulmonary hypertension and
hypoxic respiratory failure. There was a significant reduc-
tion in the incidence of death or requirement for extracorpo-
real membrane oxygenation (ECMO). However, the authors
emphasized that results of iNO in term infants cannot be
extrapolated to the premature infants because of different
pathophysiology, different inclusion criteria, and different
outcomes assessed [8]. Although initially investigated for
its pulmonary vasodilating effect, it has become clear that
the potential pulmonary effects of iNO are multiple and
complex. There are pro-oxidant and anti-oxidant effects
[12] and in experimental animal models of neonatal chronic
lung disease, pulmonary structure and function are pro-
tected by iNO [13], suggesting that there are direct effects
which could potentially reduce chronic lung disease.
Several randomized controlled trials have been conducted
in preterm infants to determine whether iNO reduces the
rates of death and/or chronic lung disease [14-26]. The
results of these studies appear contradictory. Some studies
have shown a reduction in lung injury, one has shown a
reduction in cerebral injury, and several others have shown
no effect. The different patient characteristics and different
trial characteristics within these trials may explain this dif-
ference.
Summary of aggregate data systematic review in 2007
The most recent Cochrane review includes 11 studies and
3,370 participants [27]. These studies differ not only in
their design and intervention, but in the eligible patient pop-
ulations. For example, Schreiber 2003 and Kinsella 2006
studied the routine use of inhaled NO in all intubated pre-
term infants who had a relatively low oxygen requirement
and severity of illness at intubation [22,20]. The studies by
Van Meurs et al [26] and the INNOVO study group from
the UK [18], in contrast, only enrolled patients with severe
hypoxic respiratory failure and as a result had extremely
high incidences of the combined outcome of death or CLD.
The entry criteria also differed with most studies enrolling
infants in the first 48 hours, but Ballard et al [14,15]
enrolled infants between 7 and 21 days who were at high
risk of developing CLD. Hence, the review authors divided
these trials into three categories based on different entry cri-
teria: entry in the first three days of life according to oxy-
genation criteria, routine use in intubated preterm babies
and later enrolment based on an increased risk of CLD. The
results showed there was a marginally significant reduction
in death or CLD at 36 weeks with a relative risk of 0.91
(95% CI 0.84-0.99) in studies with routine use of iNO in
intubated preterm infants. However, trials of early treatment
of infants based on oxygenation criteria or of later enrol-
ment based on the risk of CLD did not demonstrate signifi-
cant benefit of iNO for the primary end point of death or
CLD at 36 weeks, when analyzed according to standard
aggregate data meta-analytic techniques. Almost all infor-
mation from late enrolled babies is derived from a single
large study (Ballard et al) which reported a significant
reduction in the outcome of death or CLD [14,15]. These
data were analyzed using a new method (multiple outputa-
tion) to account for potential confounding effects of enroll-
ing infants from multiple gestations, of whom only the first
eligible infant was randomized. One way in which to con-
firm or refute these results and to determine whether certain
patient or treatment characteristics may predict benefit from
inhaled Nitric Oxide in premature infants is by means of an
individual patient data meta-analysis.
The advantages of an individual patient data meta-analy-
sis over a meta-analysis based on aggregate data are as fol-
lows:
• It is possible to ensure uniformity in defining patient
characteristics and outcome measures.
• Such analysis can assess the relationship between
patient-level characteristics and treatment effect, result-
ing in a differentiation of the treatment effect according
to risk profiles.
• A more accurate assessment of how trial characteris-
tics may affect response is feasible.
• Information on long-term outcome can be updated.
• It is possible to develop predictive models using mul-
tivariate regression analyses.
Objectives
1. To determine whether inhaled Nitric Oxide in pre-
term infants receiving assisted ventilation improves sur-
vival without morbidity, specifically without CLD or
major neurological injury.
2. To determine whether the effects of inhaled Nitric
Oxide differ according to the risk profile of the patient
in terms of gestational age at birth, severity of illness,
antenatal steroid use, postnatal age at the time of ran-Askie et al. BMC Pediatrics 2010, 10:15
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domization, ventilation mode at randomization, admin-
istration of exogenous surfactant, inhaled Nitric Oxide
dosage and duration of administration.
Methods
Inclusion criteria for studies
Study design: Studies will be included if they are random-
ized controlled trials.
Participants: Preterm infants (less than 37 weeks gesta-
tion) receiving assisted ventilation. Intervention: Inhaled
Nitric Oxide compared to control.
Search strategy
The standard search strategy of the Cochrane Neonatal
Review Group will be used to identify potentially eligible
studies. This involves extensive searching of bibliographic
databases such as MEDLINE, EMBASE.com, The
Cochrane Controlled Trials Register and Healthstar from
1985 to 2009. The terms "Nitric Oxide" and "newborn" will
be used and the search limited to clinical trial. The abstracts
of the Pediatric Academic Societies will also be searched
from 2000 to 2009. In addition, all members of the Collab-
orative Group will be asked to notify the group of any
unpublished trials of which they are aware. See Table 1 for
the citations of known eligible studies at October 2009 and
Table 2 for a description of these studies.
Data management
De-identified individual patient data provided by the Col-
laborators (see Additional file 1 for the suggested coding
sheet and Additional file 2 for the data provision form) will
be recoded as required and stored in an electronic database
at the Data Coordination Centre. Electronic data will be
located on a secure password-protected network server.
Copies of hardcopy data will be stored in locked filing cab-
inets until converted into electronic format, and will then be
securely destroyed. Only authorized personnel will have
access to this data.
The data will be checked with respect to range, internal
consistency, consistency with published reports and missing
items. Trial details such as randomization, methods and
intervention details will be crosschecked against published
reports, trial protocols and data collection sheets. Inconsis-
tencies or missing data will be discussed with the individual
trialists, and attempts will be made to resolve any discrep-
ancies by consensus. Each trial will be analyzed individu-
ally and the resulting analyses and trial data will be sent to
the trialists' for verification.
Data items to be requested from the trialists
Trial-level information: obtained from the trial protocol
and/or the trialists
1. Dates the trial opened and closed to accrual
2. Number of patients randomized
3. Informed consent procedures
Table 1: MAPPiNO Collaboration: citations for eligible trials 
as at October 2009
Trial identifier Main citation
Ballard 2006 Ballard RA, Truog WE, Cnaan 
A, et al. Inhaled Nitric Oxide 
in preterm infants 
undergoing mechanical 
ventilation. New England 
Journal of Medicine 2006; 
355(4):343-53.
Dani 2006 Dani C, Bertini G, Pezzati M, et 
al. Inhaled Nitric Oxide in very 
preterm infants with severe 
respiratory distress 
syndrome. Acta Pediatrica 
2006; 95: 1116-1123.
Hascoet 2005 Hascoet JM, Fresson J, Claris 
O, et al. The safety and 
efficacy of Nitric Oxide 
therapy in premature infants. 
Journal of Pediatrics 2005; 146 
(3):318-23.
INNOVO 2005 INNOVO. Neonatal 
ventilation with inhaled 
Nitric Oxide versus 
ventilatory support without 
inhaled Nitric Oxide for 
preterm infants with severe 
respiratory failure: the 
INNOVO multicentre 
randomized controlled trial. 
Pediatrics 2005; 115 (4):926-
36.
Kinsella 1999 Kinsella JP. Inhaled Nitric 
Oxide in premature neonates 
with severe hypoxaemic 
respiratory failure: a 
randomised controlled trial. 
Lancet 1999; 354(9184):1061.
Kinsella 2006 Kinsella JP, Cutter GR, Walsh 
WF, et al. Early inhaled Nitric 
Oxide therapy in premature 
newborns with respiratory 
failure. New England Journal 
of Medicine 2006; 355(4):354-
64.Askie et al. BMC Pediatrics 2010, 10:15
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4. Methods of random allocation
5. Stratification factors used
6. Methods of allocation of concealment
7. Blinding of outcome assessment
8. Details of the intervention in the experimental arm
• Inhaled Nitric Oxide concentration
• Durations allowed
• Protocol for weaning
• Target oxygen saturation range
• Target blood gas range
9. Details of the intervention in the control arm
• Target oxygen saturation range
• Target blood gas value range
10. Criteria for permitted crossover from the assigned
treatment
11. Criteria for failure of assigned treatment
12. Details of surfactant replacement therapy, if deter-
mined by the protocol
13. Criteria for postnatal treatment with systemic corti-
costeroids
Patient-level information: characteristics at study entry
1. Unique identification coded for anonymity
2. Time or postnatal age at intubation
3. Time or postnatal age at randomization
4. Gestational age at birth
5. Birth weight
6. Antenatal corticosteroid therapy, complete (>24
hours) or not
7. Sex
8. Race
9. Inborn/outborn status
Mercier 1999 Mercier JC, Thebaud B, 
Onody P. Early compared 
with delayed inhaled Nitric 
Oxide in moderately 
hypoxaemic neonates with 
respiratory failure: a 
randomised controlled trial. 
Lancet 1999; 354(9184):1066.
Schreiber 2003 Schreiber MD, Gin-Mestan K, 
Marks JD, et al. Inhaled Nitric 
Oxide in Premature Infants 
with the Respiratory Distress 
Syndrome. New England 
Journal of Medicine 2003; 
349(22):2099-107.
Mestan KKL, Marks JD, Hecox 
K, et al. Neurodevelopmental 
Outcomes of Premature 
Infants Treated with Inhaled 
Nitric Oxide. New England 
Journal of Medicine 2005; 
353(1):23-32.
Srisuparp 2002 Srisuparp P, Heitschmidt M, 
Schreiber MD. Inhaled Nitric 
Oxide therapy in premature 
infants with mild to 
moderate respiratory distress 
syndrome. J Med Assoc Thai 
2002; 85(Suppl 2): S469-S478.
Su 2008 Su PH, Chen JY. Inhaled Nitric 
Oxide in the management of 
preterm infants with severe 
respiratory failure. Journal of 
Perinatology 2008; 28: 112-
116.
Subhedar 1997 Subhedar NV, Ryan SW, Shaw 
NJ. Open randomised 
controlled trial of inhaled 
Nitric Oxide and early 
dexamethasone in high risk 
preterm infants. Arch Dis 
Child Fetal Neonatal Ed 1997; 
77(3): F185-F190.
Subhedar NV, Shaw NJ. 
Changes in oxygenation and 
pulmonary haemodynamics 
in preterm infants treated 
with inhaled Nitric Oxide. 
Arch Dis Child Fetal Neonatal 
Ed 1997; 77(3):F191-F197.
Table 1: MAPPiNO Collaboration: citations for eligible trials 
as at October 2009 (Continued)
Van Meurs 2005 Van Meurs KP, Wright LL, 
Ehrenkranz RA, et al. Inhaled 
Nitric Oxide for Premature 
Infants with Severe 
Respiratory Failure. New 
England Journal of Medicine 
2005; 353(1):13-22.
EUNO 2008 (completed RCT 
awaiting publication)
JC Mercier, H. Hummler, X 
Durrmeyer, et al. The effects 
of inhaled Nitric Oxide on the 
development of 
bronchopulmonary dysplasia 
in preterm infants: the 'EUNO' 
multicentre randomised 
clinical trial. Abstract: 
European Academy of 
Pediatrics, Nice, France, 
October 25, 2008.
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Table 2: MAPPiNO Collaboration: description of eligible trials as at October 2009
Study Participants Intervention Primary outcome
Ballard 2006 582 infants <1250 g and <32 wks 
on assisted ventilation at 7-21 
days (or, if <800 g, on CPAP)
Inhaled NO at 20 ppm initial dose for 48 to 96 
hours, then dose subsequently decreased to 
10, 5, and 2 ppm at weekly intervals, with a 
minimum treatment duration of 24 days
Survival without BPD 
at 36 wks 
postmenstrual age
Dani 2006 40 infants <30 wks ventilated 
with severe RDS: FiO2 >0.5 and 
arterial-alveolar oxygen ratio < 
0.15 despite surfactant 
treatment
Inhaled NO at 10 ppm for 4 hours followed by 6 
ppm. Weaning (decrease by 2 ppm every 3 hrs) 
started at 72 hrs or when the infant was 
extubated or when the FiO2 <0.3 with a mean 
airway pressure <8 cmH2O
Death or BPD (oxygen 
requirement at 36 
weeks 
postconceptional 
age) in survivors
Hascoet 2005 860 infants <32 wk enrolled at 
birth; n = 145 infants were 
eligible for study gas as had 
hypoxic respiratory failure 
(defined as need for mechanical 
ventilation, FiO2>0.40 and 
arterio-alveolar O2 ratio <0.22) at 
6-48 hrs age
Inhaled NO was administered starting at 5 
ppm, with adjustments allowed depending on 
response up to a maximum of 10 ppm.
Subjects were allowed to receive (unblinded) 
iNO in either group if they developed refractory 
hypoxemia.
Intact survival at 28 
days (defined as alive 
without need for 
oxygen 
supplementation or 
IVH >grade 1 or 
refractory 
hypoxaemia (need for 
100% oxygen with 
PaO2<50 mmHg) and 
PCO2 <50 mmHg)
INNOVO 2005 108 preterm infants (<34 wks) 
less than 28 days of age with 
severe respiratory failure 
requiring ventilator support and 
have had surfactant when 
appropriate
Inhaled NO usually at 5 ppm, up to 40 ppm 
based on response criteria (satisfactory 
response: increase in PaO2 >22.5 mmHg after 
15 minutes iNO)
1) Death or severe 
disability at 1 year 
corrected age; and
2) Death before 
discharge or 
continued oxygen 
need at 36 wks pma 
and/or at expected 
date of delivery
Kinsella 1999 80 preterm infants (</= 34 
weeks) aged 7 days or less, with 
a/A ratio <0.1 on two sequential 
arterial blood measurements 
despite mechanical ventilation 
and surfactant treatment
Inhaled NO at 5 ppm for 7 days after which 
periods of no study gas were tried; threshold 
criteria for gas re-start was an increase of >/
=15% in OI; maximum treatment duration was 
14 days
Survival to discharge
Kinsella 2006 793 preterm infants < 34 wks, 
with respiratory failure needing 
assisted ventilation in first 48 
hours of life
Inhaled NO at 5 ppm for 21 days or until 
extubation
Death or BPD (need 
for supplemental 
oxygen or mechanical 
ventilation at 36 wks 
pma and abnormal 
CXR)Askie et al. BMC Pediatrics 2010, 10:15
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Schreiber 2003 207 infants < 34 wks and < 2000 
g birth weight, < 72 hours of age, 
and intubated/ventilated for 
RDS, having had exogenous 
surfactant
Inhaled NO starting at 10 ppm for 12-24 hrs, 
then 5 ppm for 6 days, then weaned by 1 ppm 
every 6 hrs if PaO2 did not decrease by more 
than 15% until extubation; 2 × 2 factorial trial of 
iNO vs control gas and HFOV vs CMV
Death or CLD 
(supplemental 
oxygen and CXR 
showing persistent 
parenchymal lung 
disease at 36 weeks 
pma) among 
surviving infants
Srisuparp 2002 34 infants < 2000 g, ventilated 
after surfactant with an arterial 
catheter and less than 72 hours 
of age + satisfying severity of 
illness criterion: OI >4 if 
birthweight<1000 g; >6 if 1001-
1250 g; >8 if 1251-1500 g; >10 if 
1501-1750 g; and >12 if 1751-
2000 g birthweight
Inhaled NO at 20 ppm for 6-12 hrs, then 
reduced to 10 ppm, and weaned to 5 ppm in 
the next 12 hrs; weaning tolerated if PaO2did 
not decrease by more than 15%; once 5 ppm 
achieved, weaning was attempted at 1 ppm a 
time as tolerated until gas discontinued; 
maximum duration allowed was 7 days
Severe 
intraventricular 
hemorrhage (grade 3 
or 4)
Subhedar 1997 42 preterm infants, < 32 wks, 
assessed at 96 hrs age for: 
mechanical ventilation since 
birth, had received surfactant, 
and high risk of developing CLD 
using a modified prediction 
score
Inhaled Nitric Oxide at 20 ppm for 2 hrs then 
weaned according to response criteria (positive 
response: decrease in OI by >=25% or 
reduction in FiO2 of >=0.10) by 5 ppm 
increments every 15 mins until 5 ppm level for 
further 72 hrs, then weaned off; 2 × 2 factorial 
trial of iNO vs control and IV dexamethasone vs 
control
Death before 
discharge or CLD 
(oxygen dependency 
for at least 28 days 
and beyond 36 wks 
pma with abnormal 
CXR)
Van Meurs 2005 420 preterm infants, < 34 weeks, 
401-1500 g birthweight, assisted 
ventilation, OI >=10 on two 
consecutive blood gases 30 min 
-12 hrs apart at least 4 hrs after 
surfactant
Inhaled Nitric Oxide initially at 5-10 ppm; 
weaning commenced 10-14 hrs after initiation 
according to response criteria (change in PaO2); 
at 30 min intervals; maximum duration was 336 
hours
Death or BPD at 36 
wks in survivors
EUNO 2008 800 preterm infants <29 wks, 
birthweight >=500 g requiring 
either surfactant or CPAP >4 
cmH2O with FiO2 >0.3 to 
maintain SpO2 ≥ 85%
Inhaled NO 5 ppm for minimum 7 to maximum 
of 21 days if still requiring respiratory support 
(including CPAP use)
Survival without BPD 
at 36 wks post 
conceptional age
a/A: arterial/alveolar oxygen ratio
BPD: bronchopulmonary dysplasia
CLD: chronic lung disease
CMV: continuous mechanical ventilation
CPAP: continuous positive airway pressure
CXR: chest X ray
FiO2: fraction of inspired oxygen
g: grams
HFOV: high-frequency oscillatory ventilation
hrs: hours
iNO: inhaled Nitric Oxide
OI: oxygenation index
pma: postmenstrual age
ppm: parts per million
RDS: respiratory distress syndrome
SpO2: oxygen saturation
wks: weeks
Table 2: MAPPiNO Collaboration: description of eligible trials as at October 2009 (Continued)Askie et al. BMC Pediatrics 2010, 10:15
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10. Type of respiratory support (endotracheal tube -
conventional or high frequency, nasal CPAP, other)
11. Ventilator rate at time of randomization
12. Components of a respiratory severity score at time
of randomization (PIP, MAP and FiO2)
13. PaCO2 at time of randomization
14. PaO2 or oxygen saturation at time of randomization
15. Use of surfactant replacement therapy
16. Type of surfactant used (natural or synthetic)
17. Postnatal age at first dose of surfactant
18. Prophylactic indomethacin
19. PDA
20. Postnatal treatment with systemic corticosteroids
21. Worst pre-randomization cranial ultrasound result
Patient-level information: data on actual study interven-
tion
1. Study gas assigned
2. Highest and starting dosage received
3. Duration of therapy
4. Any re-treatment after study period
5. Other drugs in same pathway
6. Change in ventilation mode during therapy (CMV to
HFV or vice versa)
7. Failure of assigned treatment
8. Need for treatment crossover during study period
Patient-level information: data on neonatal outcome
1. Mortality and age at death
2. Duration of mechanical ventilation
3. Duration of oxygen therapy
4. Duration of any respiratory support (mechanical ven-
tilation, CPAP or oxygen)
5. Gross pulmonary air leak (pneumothorax or other
gross air leak including pneumomediastinum, pneumo-
pericardium or pneumoperitoneum)
6. Pulmonary interstitial emphysema
7. Pulmonary hemorrhage
8. Worst post-randomization cranial ultrasound result
(including acute periventricular hemorrhage such as
subependymal, intraventricular or intracerebral)
9. Ventricular dilatation at any stage
10. Cystic periventricular leukomalacia
11. Worst stage of retinopathy of prematurity (ROP)
12. Threshold ROP
13. Surgical or laser therapy for ROP
14. Duration of hospital stay
15. Home oxygen therapy
Planned analyses
Binary outcomes will be analyzed using log-binomial
regression models adjusting for trial differences by includ-
ing the trial variable in the model specification. Exponenti-
ating the parameter estimate for treatment from a log-
binomial regression model produces a relative risk for treat-
ment.
Outcomes between siblings from multiple births are
highly correlated and must be accounted for in the analysis.
There are two main methods of adjusting for such 'clus-
tered' data which will be utilized in this study. The primary
method will be the multiple outputation approach. This
method involves randomly selecting one patient from each
sibling cluster and running the analysis on this set of inde-
pendent data to obtain an estimate of the effect   and an
estimate of its variance  . This process is then
repeated N times. The average of the estimated   's from
each iteration   is used as the estimate of the overall
effect and an estimate of the variance is given by the aver-
age of the variances   minus the variance of the effect
estimates  [28]. This method involves no addi-
tional assumption about correlations between siblings and
therefore avoids problems of numerical instability when fit-
ting the models.
As a sensitivity analysis, additional methods of account-
ing for correlations within the data will be used on the pri-
mary outcomes. For example generalized estimating
equations (GEE) may be used to analyse the two main end-
points of interest (death or CLD and neurological injury).
The GEE model is a repeated measures model for binary
outcomes which accounts for the correlation between sib-
lings.
Continuous normally distributed endpoints will be ana-
lyzed using a linear fixed effects model. Additionally the
treatment by trial interaction will be assessed to investigate
possible heterogeneity of treatment effects [29]. The overall
estimated mean and standard deviation within each treat-
ment group will be presented along with the mean differ-
ence in treatment effect and its 95% confidence interval
with p value. If the data do not meet the assumptions for the
model then transformations or alternative models will be
investigated.
The MAPPiNO Collaboration aims to collect all the
available worldwide individual patient data for preterm
infants randomized in clinical trials assessing the effect of
inhaled Nitric Oxide. Currently there is a commitment to
provide data from 3298 infants in 11 trials (92% of world-
wide data). A sample size of this magnitude would have at
least 89% power to detect relative changes of 10% in the
risk of death or chronic lung disease (main outcome) for the
treated group across a range of plausible baseline event
rates (55-75%) with a two sided α = 5% and 1:1 ratio for
number treated to control.
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A summary of the planned analyses is listed below. A
detailed analysis plan is outlined in a separate document
and available upon request.
Outcomes to be analyzed
The main analyses comparing the effect of inhaled Nitric
Oxide to standard therapy will be undertaken for the out-
comes listed below. The planned subgroups and sensitivity
analyses will be restricted to the main outcomes.
a. Primary outcomes
• Death or chronic lung disease (CLD) using the best
available definition (alive and oxygen dependent at 36
weeks postmenstrual age (PMA) if calculable, other-
wise trialists' own definition)
• Severe adverse neurological event after randomization
(intracranial hemorrhage (IVH) grade III or IV, or cystic
periventricular leukomalacia (PVL) or other patholo-
gies such as periventricular echodensity, periventricular
cysts, ventriculomegaly or hydrocephalus)
b. Secondary outcomes
• Death at any time, by 36 weeks PMA and at discharge
• Severe IVH (grade III or IV) with and without adjust-
ment for baseline IVH severity
• Survivors without CLD at 36 weeks PMA
• Severe adverse neurological event (IVH grade III or
IV, or PVL or other pathologies such as periventricular
echodensity, periventricular cysts, ventriculomegaly or
hydrocephalus) with and without adjustment for base-
line status
• Postnatal steroid use
• Gross pulmonary air leak (at least one of the follow-
ing: pneumothorax, pneumomediastinum, pneumoperi-
toneum or pneumopericardium)
• Pulmonary hemorrhage
• Failure of assigned treatment
• Duration of oxygen therapy
• Duration of hospital stay
• Home oxygen therapy
• Severe retinopathy of prematurity (ROP stage >=3;
surgical or laser therapy for ROP)
• Postmenstrual age when ETT ceased
• Postmenstrual age when respiratory support ceased
• Postmenstrual age when discharge from hospital
c. Additional outcome
• In addition, CLD at 36 and 28 weeks postnatal age,
CLD as classified by the trialist and CLD classified
using the best available definition (alive, oxygen depen-
dent at 36 weeks or trialists' own definition) will be
assessed. However it is noted that since these outcomes
can only be assessed for babies who survive to these
time points, these do not constitute ITT analyses nor are
they randomized comparisons.
Planned subgroup analyses
One of the strengths of individual patient data meta-analy-
ses is that they allow subgroup analyses to be performed.
For both main endpoints, subgroup analyses will be under-
taken to determine if the effect of iNO treatment differs
depending on patient-level characteristics. That is, are there
any particular patient characteristics that determine who
may benefit from inhaled Nitric Oxide. These analyses will
allow us to take into account each individual infant's own
characteristics rather than relying on summary measures of
the average risk profile of all patients in an individual trial.
We will examine the following characteristics:
1. Gestational age at birth
2. Birth weight
3. Postnatal age at entry into the study
4. Severity of lung disease (at study entry)
5. Inhaled Nitric Oxide dosage
6. Duration of therapy
7. Measure of iNO exposure (incorporating dose and
duration)
8. Antenatal steroid administration
9. Postnatal steroids administration before initiation of
iNO
10. Ventilation mode at randomization
11. Administration of exogenous surfactant
12. Presence of pulmonary hypertension
13. Multiple birth
14. Race
Planned sensitivity analyses
The following sensitivity analyses will be performed for the
main outcomes to compare the overall estimates of treat-
ment effect calculated on all data, to estimates based on
subsets of the data with the following data removed:
• Trials with <50 study patients
• Trials with inadequate concealment of allocation or
blinding
• Trials with high rates of patient exclusions (>40%)
Planned additional analyses
Multivariable regression models will be developed to deter-
mine which patient-level characteristics are predictive of
the main outcomes.
Ethical considerations
Participants in the individual trials have previously given
informed consent to participate in their respective trial. The
data for this project are to be used for the purpose for which
they were originally collected and are available through an
agreement between all trialists of the collaborative group.
These trialists remain the custodian of their original indi-
vidual trial data at all times.
Project management
Membership of the MAPPiNO Collaboration will include
representative(s) from each of the trials contributing data to
the review with an accompanying project coordination and
data management structure as described in this section.Askie et al. BMC Pediatrics 2010, 10:15
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The membership and responsibilities of each of these
management groups are as follows:
Steering Group
The Steering Group will be responsible for project manage-
ment decisions and will meet approximately 4-6 times per
year, usually via teleconference. Membership: N Finer1
(chair), K Barrington2, R Ehrenkranz3, W Rich1, L Askie4
(data coordination manager), A Carberry4(data manager).
1 Division of Neonatology, University of California, San
Diego, USA;
2 Division of Neonatology, Centre Hospitalier Universi-
taire Ste-Justine, Montreal;
3 Department of Paediatrics, Yale University School of
Medicine, USA;
4 NHMRC Clinical Trials Centre, University of Sydney,
Australia.
Advisory Group
The aim of the Advisory Group is to facilitate representa-
tive input from the Collaborative Group to the Steering
Group if this is warranted. Membership of the Advisory
Group will be at the invitation of the Steering Group.
Collaborative Group
All potentially eligible trialists will be contacted and invited
to become members of the Collaborative Group. The corre-
sponding author for each study will be contacted in the first
instance. If there is no response, the associated statistician,
data manager and/or other authors will be contacted. This
process will be updated annually for the duration of the
project, to ensure that new trialists are offered the opportu-
nity to join the project and contribute their data.
Data Coordination Centre
The project will be coordinated from the NHMRC Clinical
Trial Centre, University of Sydney, NSW, Australia. The
Data Coordination Centre will be responsible for the daily
management of the project including correspondence,
newsletter production, maintaining current trialist contact
information, meeting and teleconference organisation, and
receipt, storage and analysis of project data as directed by
the Collaborative Group via the Steering Group.
Collaborators' meetings
All members of the Collaboration, including the Steering
Group, the Advisory Group, and representatives of each
participating trial, will be invited to attend regular collabo-
rators' meetings. The meetings will be designed to allow
maximum input from the participating trialists into the
design, conduct, analysis and reporting of the project's
results.
Publication policy
The results of the project's analyses will be presented to,
and discussed with, the Collaborative Group before presen-
tation and publication. The main manuscript will be pre-
pared by the Steering Group, and circulated to the
Collaborative Group for comment and revision. The revised
draft paper then will be circulated to all members of the
Collaborative Group for comment and agreement before
publication. Publications using these data will be authored
on behalf of the Meta Analysis of Preterm Patients on
inhaled Nitric Oxide (MAPPiNO) Collaboration, either
with specific named authors, or on behalf of the Collabora-
tion as a whole. Names of other participating Collaborators
will be acknowledged in an appropriate section of the man-
uscript.
Discussion
A recently updated meta-analysis [27] showed that inhaled
Nitric Oxide marginally reduced the incidence of death or
CLD as well as severe brain damage in two studies where
iNO was used routinely for mildly sick preterm infants.
However, uncertainty remains as a larger study (Kinsella
2006) showed no significant benefit for iNO. Trials includ-
ing very ill infants or with later iNO treatment using stan-
dard meta-analytic techniques did not demonstrate a
significant effect of iNO. Using techniques to correct for
the possible confounding effects of having infants from
multiple gestations enrolled in the same group (multiple
outputation and general estimating equations) one trial
(Ballard 2006) did show a significant reduction in the com-
bined outcome of death or CLD with treatment which com-
menced between 7 and 21 days. The best way to answer
these remaining questions is to utilize existing individual
patient data from all infants enrolled in these trials. This
approach has been described as the 'gold standard' of sys-
tematic review methodology as it allows for more powerful
and flexible analysis of both subgroups and outcomes. The
MAPPiNO Collaboration has been formed to undertake a
systematic review of all available trials, with meta-analysis
based on individual patient data, to answer these important
clinical questions. Provision of data by the participating
Collaborators commenced in 2007 and results will be ready
for presentation in 2010.
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